![IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study - eClinicalMedicine IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study - eClinicalMedicine](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/b50ba3bc-b134-4944-ba49-bb4ba79f1f8a/gr1.jpg)
IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study - eClinicalMedicine
![Associations of intensity, duration, cumulative dose, and age at start of smoking, with thyroid cancer in Chinese males: A hospital-based case–control study in Zhejiang Province Associations of intensity, duration, cumulative dose, and age at start of smoking, with thyroid cancer in Chinese males: A hospital-based case–control study in Zhejiang Province](http://www.tobaccoinduceddiseases.org/f/pictures/130350_3d31d.jpg)
Associations of intensity, duration, cumulative dose, and age at start of smoking, with thyroid cancer in Chinese males: A hospital-based case–control study in Zhejiang Province
![China vaccine efficacy: Some countries using Sinovac and Sinopharm are still seeing Covid-19 cases - CNN China vaccine efficacy: Some countries using Sinovac and Sinopharm are still seeing Covid-19 cases - CNN](https://cdn.cnn.com/cnnnext/dam/assets/210701145919-china-vaccinaton-0615-large-169.jpg)
China vaccine efficacy: Some countries using Sinovac and Sinopharm are still seeing Covid-19 cases - CNN
![UAE to offer third Chinese vaccine dose amid efficacy concerns | Coronavirus pandemic News | Al Jazeera UAE to offer third Chinese vaccine dose amid efficacy concerns | Coronavirus pandemic News | Al Jazeera](https://www.aljazeera.com/wp-content/uploads/2021/05/371834989.jpg?resize=1920%2C1080)
UAE to offer third Chinese vaccine dose amid efficacy concerns | Coronavirus pandemic News | Al Jazeera
![Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial - The Lancet Microbe Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial - The Lancet Microbe](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/5d78be82-2cd1-4ca9-bacd-58be2e4babf5/gr1.gif)
Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial - The Lancet Microbe
![IJERPH | Free Full-Text | Behavioral Intention to Get a Booster Dose of COVID-19 Vaccine among Chinese Factory Workers IJERPH | Free Full-Text | Behavioral Intention to Get a Booster Dose of COVID-19 Vaccine among Chinese Factory Workers](https://www.mdpi.com/ijerph/ijerph-19-05245/article_deploy/html/images/ijerph-19-05245-ag.png)